These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17544585)

  • 1. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.
    Masmoudi A; Toumi N; Khanfir A; Kallel-Slimi L; Daoud J; Karray H; Frikha M
    Cancer Treat Rev; 2007 Oct; 33(6):499-505. PubMed ID: 17544585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells and EBV associated malignancies.
    Li J; Qian CN; Zeng YX
    Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Epstein-Barr virus-associated malignancies.
    Long HM; Parsonage G; Fox CP; Lee SP
    Drug News Perspect; 2010 May; 23(4):221-8. PubMed ID: 20520851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ
    J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus immune response in high-risk nasopharyngeal carcinoma families in Greenland.
    Friborg J; Jarrett RF; Liu MY; Falk KI; Koch A; Olsen OR; Duncan P; Wohlfarht J; Chen JY; Melbye M
    J Med Virol; 2007 Dec; 79(12):1877-81. PubMed ID: 17935169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan.
    Hsu WL; Chen JY; Chien YC; Liu MY; You SL; Hsu MM; Yang CS; Chen CJ
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1218-26. PubMed ID: 19336547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma.
    Ambinder RF; Robertson KD; Moore SM; Yang J
    Semin Cancer Biol; 1996 Aug; 7(4):217-26. PubMed ID: 8946606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
    Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Epstein-Barr virus-associated cancers in children.
    Straathof KC; Bollard CM; Rooney CM; Heslop HE
    Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of cell immortalization mediated by EB viral activation of telomerase in nasopharyngeal carcinoma.
    Liu JP; Cassar L; Pinto A; Li H
    Cell Res; 2006 Oct; 16(10):809-17. PubMed ID: 17016469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
    Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
    Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haematological associations of Epstein-Barr virus infection.
    Okano M
    Baillieres Best Pract Res Clin Haematol; 2000 Jun; 13(2):199-214. PubMed ID: 10942621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.
    Loong HH; Ma BB; Chan AT
    Hematol Oncol Clin North Am; 2008 Dec; 22(6):1267-78, x. PubMed ID: 19010273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for nasopharyngeal cancer-a review.
    Jain A; Chia WK; Toh HC
    Chin Clin Oncol; 2016 Apr; 5(2):22. PubMed ID: 27121882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nasopharyngeal carcinomas and Epstein-Barr virus: from epidemiology and detection to therapy].
    Busson P; Ooka T; Corbex M
    Med Sci (Paris); 2004 Apr; 20(4):453-7. PubMed ID: 15124119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic approaches in nasopharyngeal carcinoma.
    Chow JC; Ngan RK; Cheung KM; Cho WC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
    [No Abstract]   [Full Text] [Related]  

  • 20. Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
    Perri F; Della Vittoria Scarpati G; Giuliano M; D'Aniello C; Gnoni A; Cavaliere C; Licchetta A; Pisconti S
    Anticancer Drugs; 2015 Nov; 26(10):1017-25. PubMed ID: 26241803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.